Latest Conference Articles

Julie Thomas, MS, DMSc, PA-C, discusses why ADHD cases may go undetected into adulthood, and the methods to treat such patients.

A phase 2 trial suggests zodasiran significantly reduces triglycerides in patients with mixed hyperlipidemia, showing dose-dependent improvements in lipid profiles.

Bonder explains key therapeutic targets in primary biliary cholangitis and why combination obeticholic acid and bezafibrate may be a promising option.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains how the adoption of 5 new diabetes subtypes may foster precision care.

Lembo describes the potential of a multi-species synbiotic for the treatment of IBS based on findings from an exploratory study he presented at DDW.

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

Vlado Perkovic, MBBS, PhD, discusses the results of the FLOW trial and their implications for clinical practice at ERA 24.

Lacy reviews key considerations for the diagnostic evaluation and treatment of abdominal bloating and distension based on his session at DDW.

Aby describes findings from a pair of studies presented at DDW exploring the prevalence and impact of financial burden in liver transplant candidates.

Krugliak Cleveland explains findings from research she presented at DDW comparing intestinal ultrasound and conventional approaches to disease monitoring in IBD.

A systematic review presented at AAPA 2024 showed insignificant differences in treatment outcomes between oral JAK inhibitors and oral steroids based on alopecia outcomes like SALT.

Sisson discusses the adoption of 2021 ATS / ERS guidelines, as well as the need for complementary testing and imagine to contextualize the full pulmonary patient.

Rezaie reviews findings from a prospective clinical trial of a novel palatable elemental diet, highlighting its 100% compliance rate and strong efficacy.

Ji Hyun “CJ” Chun, MPAS, PA-C, BC-ADM, explains the potential value of defining diabetes subtypes based on insulin, obesity and age factors.

Panaccione explains findings from GALAXI 2 and GALAXI 3 demonstrating guselkumab’s superiority to ustekinumab in Crohn’s disease, presented at DDW.

Swapnil Hiremath, MD, MPH, discusses resistant hypertension, including using an evidence-based approach to management and addressing non-adherence.

Joly explains the burden of parenteral support and the significance of new STARS data showcasing apraglutide’s potential in SBS-IF.

Sivers-Teixeira explains that while the care team should quickly expand once dementia has presented in screening, the primary care role stays consistent.

Ashley Malliett, DMSc, MPAS, PA-C, discusses the importance of timely diagnosis and initiated care, as well as contraindications for transplants and LVAD.

A cable-transmission magnetically controlled capsule endoscopy showed comparability to conventional methods in upper GI tract examinations and lesion detection.

Aaron Henry, PA-C, MSHS, discusses why preventive care opportunities are often missed in Black men, and how community-based interventions may help.

Malliett discusses the signs that a caregiver should refer to an HF specialist for advanced care options, including LVAD and heart transplant.

Alkhouri explains survodutide’s mechanism of action as a glucagon/GLP-1 receptor dual agonist and reviews key findings about its use in MASH from the interim analysis.

Data from PREEMPT CRC reveal the blood-based screening test demonstrated a 79.2% sensitivity for detecting colorectal cancer.

At the end of the study period, the median dose of daprodustat and ESA were higher among the ESA-HR cohort when compared with the non-ESA-HR group.

A detailed overview and accompanying quiz on the recommendations made by the AGA in their 2024 guideline on endoscopic eradication

End-of-study results from the phase 3 REGENERATE study were presented at DDW and highlight obeticholic acid’s trend in benefit for clinical outcomes.

Both doses of guselkumab exhibited statistical superiority on all prespecified pooled endoscopic endpoints versus ustekinumab in Crohn's disease.